Tag: litigation

RENO, N.V., July 10, 2025 (GLOBE NEWSWIRE) -- GreetEat Corporation (OTC: GEAT), a fast-growing innovator in digital social and financial platforms, today announced significant increases in user engagement across its flagship properties, GreetEat.com and WallStreetStats.io - a clear validation of its dual-focus strategy on virtual connection and intelligent investing.

BOCA RATON, FL, July 10, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today the purchase of 153,225 Solana (“SOL”) at an average purchase price of $154.85 and valued at approximately $23.72 million. Following this transaction, DeFi Dev Corp. now holds approximately 846,630 SOL and SOL equivalents, including staking rewards, making the Company the largest Solana treasury company, by both total holdings and market capitalization.

New York, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that Chief Executive Officer James Walker will participate in a fireside chat at H.C. Wainwright’s Powering the Future: Advancing Innovation Through Nuclear Virtual Conference hosted by Sameer Joshi, Senior Cleantech Analyst at H.C. Wainwright, on July 15, 2025 at 9:00 a.m., Eastern time.

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.

U.S. Developer Vows Vigorous Litigation & Project Completion
Click for Assets